JWM
KPTI icon

Janiczek Wealth Management’s Karyopharm Therapeutics KPTI Stock Holding History

Janiczek Wealth Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$15 Hold
1
– – ﹤0.01% 1084
2024
Q1 		$26 Hold
1
– – ﹤0.01% 1087
2023
Q4 		$15 Buy
+1
New +$13 ﹤0.01% 1130

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Janiczek Wealth Management's KPTI Position: Q2 2024 in Review

Janiczek Wealth Management held its Karyopharm Therapeutics (KPTI) position steady in Q2 2024 at 1 share worth $15. The position accounts for ﹤0.01% of the portfolio, ranked #1084.

Janiczek Wealth Management first reported a position in KPTI in Q4 2023 and has held it in 3 quarters since. The position peaked at $26 in Q1 2024. 114 funds tracked by Wall St. Rank hold KPTI as of Q2 2024.

  • Janiczek Wealth Management held 1 share of Karyopharm Therapeutics worth $15 as of Q2 2024.
  • Janiczek Wealth Management left its Karyopharm Therapeutics share count unchanged in Q2 2024.
  • Karyopharm Therapeutics made up ﹤0.01% of Janiczek Wealth Management's portfolio in Q2 2024, its #1084 holding.
  • Janiczek Wealth Management first reported a position in Karyopharm Therapeutics in Q4 2023 and has held it in 3 quarters since.
  • Janiczek Wealth Management's Karyopharm Therapeutics position peaked at $26 in Q1 2024.
  • 114 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2024.

Based on Janiczek Wealth Management's 13F filing for Q2 2024, filed 25 Jul 2024.